person · Reporting owner
GRAF FINCKENSTEIN FRIEDRICH
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Chief Medical Officer | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IOVANCE BIOTHERAPEUTICS, INC.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 144,087 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 7,813 · Balance 144,087 F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. |
| Common StockSEC Table I · non-derivative | Direct | 140,111 |
Reported balance
After 2026-06-05 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-05 · Tax withholding · Disposed 3,976 · Balance 140,111 F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3: Represents the common stock remaining after deducting the common stock withheld for taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 54,691 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Exercise / conversion · Disposed 7,813 · Balance 54,691 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The remaining RSUs will vest in equal quarterly installments. F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3: Represents the common stock remaining after deducting the common stock withheld for taxes.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The remaining RSUs will vest in equal quarterly installments.
F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 17:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 7,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071897 · tm2617137-3_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,691 Underlying: Common stock · 7,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 17:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 3,976 | $4.23 | $16,818.48 |
DisclosureSEC source: 0001104659-26-071897 · tm2617137-3_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,111 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 17:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 7,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071897 · tm2617137-3_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070152 · tm2616710-2_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,369 Underlying: Common stock · 8,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,473 | $3.96 | $17,713.08 |
DisclosureSEC source: 0001104659-26-070152 · tm2616710-2_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,274 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 8,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070152 · tm2616710-2_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 58,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-026448 · tm268453-3_4seq1.xml · derivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,750 Underlying: Common stock · 58,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 31,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-024762 · tm268187-3_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,504 Underlying: Common stock · 31,246 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 16,520 | $4.58 | $75,661.60 |
DisclosureSEC source: 0001104659-26-024762 · tm268187-3_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,957 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 31,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-024762 · tm268187-3_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023535 · tm267902-1_4seq1.xml · derivative · entry 4 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023535 · tm267902-1_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,159 Underlying: Common stock · 8,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 7,122 | $3.79 | $26,992.38 |
DisclosureSEC source: 0001104659-26-023535 · tm267902-1_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,231 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 12,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023535 · tm267902-1_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118170 · tm2532666-4_4seq1.xml · derivative · entry 6 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,907 Underlying: Common stock · 3,906 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,984 | $2.14 | $4,245.76 |
DisclosureSEC source: 0001104659-25-118170 · tm2532666-4_4seq1.xml · nonDerivative · entry 4 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,656 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 3,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118170 · tm2532666-4_4seq1.xml · nonDerivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118170 · tm2532666-4_4seq1.xml · derivative · entry 5 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,949 Underlying: Common stock · 8,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,464 | $2.23 | $9,954.72 |
DisclosureSEC source: 0001104659-25-118170 · tm2532666-4_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,734 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 8,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118170 · tm2532666-4_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087546 · tm2525186-2_4seq1.xml · derivative · entry 4 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,738 Underlying: Common stock · 8,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087546 · tm2525186-2_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,813 Underlying: Common stock · 3,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 6,448 | $2.19 | $14,121.12 |
DisclosureSEC source: 0001104659-25-087546 · tm2525186-2_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,409 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 12,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087546 · tm2525186-2_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:49 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056438 · tm2517077-3_4seq1.xml · derivative · entry 4 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,528 Underlying: Common stock · 8,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:49 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056438 · tm2517077-3_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,720 Underlying: Common stock · 3,906 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:49 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 6,448 | $1.76 | $11,348.48 |
DisclosureSEC source: 0001104659-25-056438 · tm2517077-3_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,160 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:49 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 12,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056438 · tm2517077-3_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 01:06 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021869 · tm258333-8_4seq1.xml · derivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Underlying: Common stock · 93,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 58,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021055 · tm258333-1_4seq1.xml · derivative · entry 4 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,317 Underlying: Common stock · 58,590 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021055 · tm258333-1_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,626 Underlying: Common stock · 3,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 33,470 | $4.04 | $135,218.80 |
DisclosureSEC source: 0001104659-25-021055 · tm258333-1_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,913 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 62,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021055 · tm258333-1_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 23:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004204 · tm253469-2_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 23:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,578 | $5.89 | $9,294.42 |
DisclosureSEC source: 0001104659-25-004204 · tm253469-2_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,886 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 23:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004204 · tm253469-2_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-125542 · tm2430163-1_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,533 Underlying: Common stock · 3,906 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,982 | $9.07 | $17,976.74 |
DisclosureSEC source: 0001104659-24-125542 · tm2430163-1_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,651 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 3,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-125542 · tm2430163-1_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 22:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-109277 · tm2426276-2_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,813 Underlying: Common stock · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 22:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,428 | $9.77 | $13,951.56 |
DisclosureSEC source: 0001104659-24-109277 · tm2426276-2_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,727 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 22:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-109277 · tm2426276-2_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:54 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 23,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097490 · tm2423453-3_4seq1.xml · derivative · entry 6 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,437 Underlying: Common Stock · 23,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The remaining RSUs will vest on the one-year anniversary of the initial grant date, as provided in footnote 8. F7 · derivative.expiration_date: The remaining RSUs will vest on the one-year anniversary of the initial grant date, as provided in footnote 8. F8 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:54 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097490 · tm2423453-3_4seq1.xml · derivative · entry 5 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,439 Underlying: Common stock · 3,906 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:54 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 11,891 | $10.85 | $129,017.35 |
DisclosureSEC source: 0001104659-24-097490 · tm2423453-3_4seq1.xml · nonDerivative · entry 4 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,342 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:54 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 23,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097490 · tm2423453-3_4seq1.xml · nonDerivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:54 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,983 | $10.85 | $21,515.55 |
DisclosureSEC source: 0001104659-24-097490 · tm2423453-3_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,795 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:54 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 3,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097490 · tm2423453-3_4seq1.xml · nonDerivative · entry 1 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| July 15, 2024 Filed Jul 18, 2024 00:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-080617 · tm2419709-2_4seq1.xml · derivative · entry 3 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,626 Underlying: Common stock · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| July 15, 2024 Filed Jul 18, 2024 00:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,428 | $8.68 | $12,395.04 |
DisclosureSEC source: 0001104659-24-080617 · tm2419709-2_4seq1.xml · nonDerivative · entry 2 GRAF FINCKENSTEIN FRIEDRICH · CIK 0001782981 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,871 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.